Fig. 2: Interference with endogenous oncogene expression via the HOPE strategy in vitro.
From: NF-κB-activated oncogene inhibition strategy for cancer gene therapy
A Representative fluorescence images of stained cancer cells at 24 h post transfection. Stain, acridine orange/ethidium bromide (AO/EB); scale bar, 50 μm. B Bar chart showing the numbers of viable cancer cells after transfection with the HOPE plasmids. SiHa, BGC823, and A549 cells were counted in the fluorescence images of AO/EB-stained cells with ImageJ2 software (n = 3 images). C Representative fluorescence images of AO/EB-stained normal cells at 24 h post transfection. Scale bar, 50 μm. D Bar chart showing the numbers of viable normal cells after transfection with the HOPE plasmids. HL7702, GES-1 and MRC-5 cells were counted in the fluorescence images of AO/EB-stained cells with ImageJ2 software (n = 3 images). pHOPE-NT/hTERT/hPLK1/hMYC/hKRAS, HOPE plasmids targeting no transcript and the human oncogenes TERT, PLK1, MYC, and KRAS.
